Eton gains as hormonal disorder therapy undergoes FDA review
Source: SeekingAlpha
2025-07-08 07:33:09 ET
More on Eton Pharmaceuticals
- Eton Pharmaceuticals: Rapid Revenue Growth And Pipeline Catalysts Point To More Upside
- Eton Pharmaceuticals Set To Dominate Orphan Drug Niche
- Eton Pharmaceuticals, Inc. (ETON) Q1 2025 Earnings Call Transcript
- Eton Pharma wins FDA nod for oral hydrocortisone solution
- Eton outlines path to $100M near-term revenue with ET-400 launch and Increlex growth
Read the full article on Seeking Alpha
For further details see:
Eton gains as hormonal disorder therapy undergoes FDA review
Eton Pharmaceutcials Inc.
NASDAQ: ETON
ETON Trading
0.97% G/L:
$18.69 Last:
83,953 Volume:
$19.08 Open:
ETON Latest News
March 03, 2026 04:30:00 pm
Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, March 19, 2026
March 02, 2026 07:27:44 am
Eton Pharmaceuticals Expands Rare Disease Portfolio Through Acquisition of U.S. Commercialization Rights to HEMANGEOL® (propranolol hydrochloride) Oral Solution
February 25, 2026 01:47:00 pm
Eton Pharmaceuticals Announces U.S. FDA Approval for DESMODA(TM) (desmopressin acetate) Oral Solution
February 20, 2026 06:50:00 am
Eton Pharmaceuticals to Participate at Leerink Partners Global Healthcare Conference on Wednesday, March 11th
ETON Stock Data
$408,699,233
22,518,684
14.05%
24
N/A
Pharmaceuticals
Healthcare
US
Deer Park
